New On Robinhood
You can buy or sell Elanco and other stocks, options, ETFs, and crypto commission-free!
Elanco Animal Health, Inc. engages in the innovation, development, manufacture and market products for companion and food animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. Read More The Companion Animal Disease Prevention category engages in the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The Companion Animal Therapeutics category provides the details of broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. It also focuses on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. The Food Animal Ruminants & Swine category develops animal food products used in ruminant and swine production. The company was founded on May 3, 2018 and is headquartered in Greenfield, IN.
52 Week High
52 Week Low
New On Robinhood
Meat Fish Dairy
Elanco Appoints Four New Members to Board of Directors
GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today announced the appointment of four new members to the Board of Directors. The new members will serve on staggered terms, creating a nine-member Board. The Board was initially established in September 2018 when Elanco became a publicly traded company following its separation from Eli Lilly and Company. The appointments follow Lilly’s full divestiture of Elanco, making Elanco a fully independent company. The Board will hel...
Elanco Animal Health (NYSE:ELAN) Begins Trading After Eli Lilly (NYSE:LLY) Split
Elanco Animal Health Inc (NYSE: ELAN), a global animal health company, began trading Monday as a fully standalone entity after completing a split from Eli Lilly And Co (NYSE: LLY). What Happened Elanco completed its initial public offering in September 2018, at which point Eli Lilly was a majority shareholder with an 80.2-percent stake. In early February, the parent company said it would divest the remaining stake. Shareholders could exchange all, some or none of their Eli Lilly stock. The ultimate exchan...
PR NewswireMar 11
Lilly Announces Preliminary Results of Elanco Exchange Offer
INDIANAPOLIS, March 11, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that, based on preliminary results, its previously-announced offer for shareholders to exchange their shares of Lilly common stock for shares of Elanco Animal Health Incorporated (NYSE: ELAN) owned by Lilly was oversubscribed.
Expected May 9, Pre-Market